anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.
PURPOSE: A method of producing loess water-mud by blending water with loess, aging and then introducing ozone thereinto is provided. A bathing apparatus allows a bather to simultaneously enjoy relaxing comforts using the loess water mud. CONSTITUTION: Loess is ground, mixed with water in ratio of 2:8, aged for 5 to 24hr and then filtered to give loess water(jijangsu). The loess water is introduced with ozone and mud to give loess water-mud. A bathing apparatus comprises: a storage tank(1) for storing loess water-mud(20); a bathroom(4) arranged on one side of the storage tank to allow a person to sit down on a seat(17) and take a bath or a shower; a space part(7) formed at the lower part of the storage tank and bathroom; a connection pipe(5) installed with a first pump(6) to supply the loess water-mud to the bathroom; and a discharge pipe(9) arranged at the lower part of the storage tank and bathroom and attached with a control part to control the amount and temperature of mud. The storage tank is equipped with a heating line(11) of a heating apparatus to heat loess water-mud.
<P>PROBLEM TO BE SOLVED: To provide a lactic bacterium variant which has improved oxygen resistance and in which a riboflavin transporter gene is wholly or partially inactivated.  <P>SOLUTION: Mutation is induced in Lactobacillus gasseri OLL 2716 strain by using disparity mutagenesis at first, and a variant having improved survivability (improved oxygen resistance) in the presence of the oxygen is screened by preserving the obtained variant at a low temperature in an oxygen-filled condition. As a result, it is clarified that the mutation in the riboflavin transporter gene takes part in the enhancement of the oxygen resistance. The inventors has succeeded in the creation of the variant having the improved survivability when preserved at the low temperature in the oxygen-filled condition by inducing the mutation in the riboflavin transporter gene in the bacterium of Lactobacillus gasseri or the bacterium of Lactobacillus delbrueckii subsp. bulgaricus.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving metformin, the patient should be observed closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin, the patient should be observed closely for hypoglycemia.

In healthy volunteers, the pharmacokinetics of metformin and propranolol and metformin and ibuprofen were not affected when co-administered in single-dose interaction studies.

Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.
A labeling reagent having a distinct Raman, or surface enhanced Raman, spectral signature is used for the control and analysis samples. The labeling reagents can be fluorescent dyes with different isotopic substituents, such as the substitution of some hydrogen atoms for deuterium atoms. Such labeling does not have any detectable effect on separation retention. Raman spectroscopy is used for detection purposes. By combining SERS and SERRS, a concentration ratio prediction error of less than 3% can be obtained over four orders of magnitude of total concentration with up to a factor of 3 concentration ratio range. The method is reliable, reproducible and more sensitive than methods based on absolute SERS/SERRS intensity correlations, with no internal standard, or using a different molecule (rather than an IEIS) as a SERS/SERRS internal standard.
Computer-aided telemedical evaluation is described. A computing environment can receive a video comprising frames of a subject in motion. The computing environment can identify one or more anatomical features of the subject and determine one or more gait cycle patterns for the anatomical features by tracking motion of the anatomical features over a number of frames of the video. The computing environment can also examine the gait cycle patterns to identify symmetry, asymmetry, and other characteristics in the gait cycle patterns with respect to each other, the anatomical features of the subject, and/or inanimate features of the surroundings. Based on the examination, the computing environment can also provide an evaluation of the subject in the video. The evaluation can include the identification of one or more limbs associated with lameness in the subject. Care can then be administered to the subject, in part, based on the evaluation.
The invention provides a compound Chinese medicinal granule for pet health care and a preparation method thereof. The compound Chinese medicinal granule consists of the following 9 drugs: forsythia, dried tangerine peel, Green Tangerine Peel, Curcuma Zedoary, cinnamon, good ink, betel nut, semen pharbitidis, and Rhizoma Sparganii. Effective components are extracted from the drugs respectively according to certain technical method. The method is characterized by increasing the pinellia ternate dosage and reducing the toxicity to 1/1000 by certain preparation process. The whole compound is rigorous, the process is simple and reasonable, and the prepared granule is convenient to use and has a long period of validity. Thus, the granule has better curative effect and broader indications, and realizes the purposes of safe, effective, stable and convenient use to pets.
The invention relates to a polypeptide and tumor targeting peptide thereof, a tumor detection reagent, a tumor operation navigation contrast medium and a tumor targeting drug, belonging to the field of biological medicine. The polypeptide is selected from the group consisting of Va-C, Va-RA, Va-RS, Va-RK, Va-KRA, Va-RL; the amino acid sequence of Va-C is shown in SEQ ID NO. 1; the amino acid sequence of Va-RA is shown in SEQ ID NO. 2; the amino acid sequence of the Va-RS is shown in SEQ ID NO. 3; the amino acid sequence of Va-RK is shown in SEQ ID NO. 4; the amino acid sequence of the Va-KRA is shown as SEQ ID NO. 5; the amino acid sequence of the Va-RL is shown in SEQ ID NO. 6. Compared with the existing commonly used tumor targeting peptide such as P47, the polypeptide of the invention has better targeting property, and can be applied to clinical detection, surgical navigation and treatment of tumors.
The invention discloses an ECMO simulation model, an ECMO treatment system simulation model and an ECMO simulation method. The ECMO simulation model includes a fluid circulation model for simulating a blood flow path of the ECMO apparatus, a gas oxygenation model for simulating an oxygen supply path of the ECMO, a setup module, and a calculation module. The fluid circulation model includes at least one fluid circulation path simulation unit, a blood draw connection node, and a first material exchange node. The bleed connection node is capable of receiving a parameter of a substance corresponding to blood of the human blood upon entering the extracorporeal membrane lung oxygenation device. The gas oxygenation model comprises at least one gas oxygenation path simulation unit and a second mass exchange node. The setup module is for setting parameters of at least one fluid circulation path simulation unit and at least one gas oxygenation path simulation unit. And the calculating module is used for calculating the parameter values of the substances of the fluid circulation path node and the gas oxygenation path node and the substance exchange amount of the first substance exchange node and the second substance exchange node.
The invention relates to a compound 18-amino acid injection containing a little amount of antioxidant and a preparation method thereof. The injection contains 0.0005w/v% to 0.005w/v% of sodium hydrogen sulfite or sodium metabisulfite or mixture which is compounded with 18 kinds of amino acids and water for injection, wherein the content of dissolved oxygen in the injection is not greater than 0.1ppm (parts per million). The preparation method comprises the following steps of: 1) preparing: putting 18 kinds of compound amino acids, the sodium hydrogen sulfite or the sodium metabisulfiteor or the mixture into a tank by filling nitrogen ceaselessly under the conditions that content of oxygen in the tank is lower than 0.1% and the content of the dissolved oxygen contained in the injection is not greater than 0.1ppm; 2) filling and sealing; and 3) sterilizing. By optimizing a production process, the oxygen content of a medicine liquid and the oxygen content of a headspace are reduced fundamentally, so that the content of the sodium bisulfite/the sodium metabisulfite which is added for ensuring that the medicine liquid is not oxidized is reduced. Thus, the compound amino acid injection which can be well tolerated by a patient is produced, namely, the safety of the injection is improved. Therefore, the phenomenon that a sufficient dose of the injection cannot be accepted by the patient because the patient is worry about toxic and side effects is avoided. As a result, the injection provided by the invention has the great significance for guaranteeing the living and the life quality of the patient.
The purposes of this multi-center, double blind randomized dose response study are: to evaluate the safety of undiluted Dryvax and Dryvax diluted at 1:5 and 1:10 in adults between the ages of 32 and 70 years who were previously vaccinated but not since 1989 and to define, with very high precision (+/-3%), the proportion of individuals who respond with a "take" 6 to 11 days after vaccination with undiluted Dryvax vaccine and Dryvax diluted at 1:5. A "take" is defined as the formation of a lesion at the site of vaccination that is consistent with the description of a successful vaccination described in the IB Secondary study objectives include defining with good precision (+/- 10%), the proportion of individuals who respond with a "take" 6 to 11 days after vaccination with a 1:10 dilution of Dryvax vaccine and exploring correlations between "takes"/ no-"take" and immune responses in all vaccine groups (antibody responses in all volunteers; and assays of cell-mediated immunity in a convenience sample consisting of 15 volunteers enrolled at each site (total N = 105) randomly distributed across the vaccine groups). Immunogenicity assays will include neutralizing antibody to vaccinia, vaccinia binding antibody, ELISPOT for gamma interferon \[Assays of cell-mediated immunity will be performed only on a convenience sample consisting of 15 volunteers enrolled at each site (total N = 105)\] and intracellular cytokine production. Primary safety endpoints include safety data regarding the three doses of vaccine in previously vaccinated subjects as assessed by adverse events reported by the subjects and/or investigators and changes observed during the scheduled clinic visits. Specific attention will be paid to the following: local reactogenicity at the site of injection: pain, tenderness, erythema, induration, regional lymphadenopathy, limitation of limb movement; systemic symptoms: fever, myalgia, fatigue, and headache; anaphylaxis, and hypersensitivity reactions; other reactions: dermatologic, neurologic, gastrointestinal (nausea/vomiting, diarrhea). The primary efficacy endpoint for this trial will be the proportion of vaccinees demonstrating a "take" 6 to 11 days after the first vaccination at each of the dose levels (undiluted and 1:5 and 1:10). Secondary endpoints are: immune responses as assessed by vaccinia neutralizing antibody measured on all subjects and binding antibody to vaccinia on all subjects and the size of the lesions observed in all subjects compared across the dilution groups. Tertiary endpoints of 15 volunteers at each site randomly distributed across the vaccine groups are cellular immune responses as assessed by: ELISPOT for gamma interferon in response to vaccinia antigens and intracellular cytokine production.
Buerger Allen exercises programme will be applied to the type 2 diabetes mellitus patients with foot ulcer. Patients in the intervention group performed daily Buerger Allen exercises for 12 weeks. Patients in the study intervention group were taught Buerger Allen exercises and were asked to exercise twice daily for 12 weeks. Individuals will be given an exercise diary, including the pictures of the exercises, to better manage this process. Reminder phone calls were made once a week to support the exercise program and increase motivation.
Choline containing compound (Cho) and creatine + phosphocreatine (Cr) have been found to be greater in the orbitofrontal cortex of depressed adolescents. In addition, Cho/Cr has been found to increase in the anterior cingulate in depressed patients with bipolar affective disorder (BPD) compared with comparison subjects. Also, BPD subjects not taking antidepressants had a significantly higher anterior cingulate Cho/Cr compared with subjects taking antidepressants or comparison subjects. Therefore it would appear the frontal lobe Cho/Cr is increased in depression. Given these findings, we are interested in looking at subjects with mania to investigate if there may also be a biological marker for mania and drug response. Mania measured using the YMRS have been associated with an increase in the anterior cingulate Ino/Cr in manic children, adolescents, and adults with bipolar affective disorder. In addition, children and adolescents who were responsive to lithium showed a decrease in Ino/Cr levels after acute lithium treatment. We will test whether Ino/Cr levels will correlate positively with manic symptoms using the YMRS, as well as whether overall Ino/Cr levels will be lower for children and adolescents receiving risperidone.

The primary aim of this study is to use proton magnetic resonance spectroscopy to look at myo-Inositol containing compounds (Ino) and creatine + phosphocreatine (Cr) in the anterior cingulate of 20 children with bipolar disorder between the ages of 6-17 years old free of risperidone treatment and 20 children with bipolar disorder after an eight-week or longer treatment with risperidone. For comparison, results will also be obtained from 20 controls (without bipolar disorder or ADHD) of the same age and gender as well as from 20 children or adolescents with a diagnosis of Attention Deficit Hyperactivity Disorder. We hypothesize that Ino/Cr levels in the anterior cingulate will correlate positively with manic symptoms using the Young mania rating scale (YMRS). Ino/Cr levels in the anterior cingulate in the anterior cingular gyrus will be lower in subjects who have received eight weeks or longer of risperidone
Allogeneic bone marrow or peripheral stem cell transplantation result in Graft-versus-Host disease. Ocular symptoms may be the first presentation of GVHD and may be seen in the absence of systemic manifestations. GVHD is categorized into acute and chronic forms as defined by 100 days after the transplant. Acute GVHD is characterized by dermatitis, hepatitis, and enteritis. Chronic GVHD involves the skin, mouth, liver, gastrointestinal tract, lungs, and eyes. Ocular GVHD is a common cause of dry eye symptoms in patients who have undergone bone marrow transplant (BMT), and can be defined as ocular surface disease in the context of GVHD. Dry eyes develop in 76% of acute GVHD patients and between 62.5% and 81.8% of chronic GVHD patients. Current treatment for ocular GVHD includes topical cyclosporine 0.05% (Restasis, Allergan). Topical loteprednol etabonate 0.5% (Lotemax, Bausch and Lomb) has been shown to be safe and efficacious in treatment of inflammatory ocular disorders, but has not been prospectively studied in ocular GVHD.

2. Hypothesis: We anticipate that topical loteprednol etabonate 0.5% will be safe and efficacious in treatment of ocular GVHD patients, and would add to the armamentarium of therapeutics for this disease. Further, by following the natural progression of the disease prior to a patient's Bone Marrow Transplant (BMT), we may elucidate a new standard of care for these patients - one that involves referral to an ophthalmologist before ocular GVHD symptoms arise.
The Kids ITP Tools (KIT) is a health-related quality of life (HRQoL) questionnaire that evaluates quality of life in children with immune thrombocytopenia (ITP). There are three formats: Child Self-Report, Parent Proxy-Report and Parent Impact-Report. This study aimed to develop a domain structure by grouping-related questions from the questionnaire into domains that independently reflect various aspects of HRQoL. The study was conducted in two phases. Phase 1 involved an online survey distributed to experts to identify conceptual domains for the KIT. Phase 2 utilized a statistical approach to analyse responses from patients with ITP and their families. A revised KIT 2.0 was ultimately developed to aid in treatment decision-making and monitoring of ITP.
PCT No. PCT/JP93/00540 Sec. 371 Date Dec. 22, 1993 Sec. 102(e) Date Dec. 22, 1993 PCT Filed Apr. 26, 1993 PCT Pub. No. WO93/22410 PCT Pub. Date Nov. 11, 1993The invention provides a process comprising treating a lanolin fatty acid with boric acid to convert hydroxy fatty acids therein to boric acid esters, subjecting the reaction mixture to vacuum distillation to fractionate the boric acid esters of hydroxy fatty acids from non-hydroxy fatty acids, hydrolyzing the boric acid esters, and subjecting the hydrolysate to vacuum distillation to provide  alpha -hydroxy fatty acids and  omega -hydroxy fatty acids, the resultant respective lanolin fatty acids and esters, and cosmetic products and drug products for external use containing them. According to the invention, pale-colored, substantially odor-free lanolin fatty acids can be obtained easily and with high efficiency and these compounds can be effectively utilized in the pharmaceutical and cosmetic field.
This study will investigate the effects of regular dosing of naltrexone for the treatment of disordered gambling. It will also examine the changes of neurological functioning to tasks associated with addiction. Converging evidence suggests that disordered gambling shares similarities with substance dependence and disordered alcohol use. Naltrexone is a medication that is used to reduce the cravings and euphoria from opioids and alcohol use and some studies have shown that it also has efficacy as a treatment for problematic gambling. Pilot data suggest the prefrontal cortex is activated for a healthy subject during a delay-discounting task, possibly indicating some consideration of the delayed value of a hypothetical money amount. If discounting rates can be correlated with treatment outcomes and neurological activation, these tasks may provide a new predictive tool for treatment outcome. However, no previous study has examined the neurological changes from pharmacological treatments of gambling. This study will provide data on the differences between pre- and post-treatment of regular naltrexone dosing for disordered gamblers
Automated techniques may be used to process three-dimensional image sets obtained via computer tomography (CT), magnetic resonance imaging (MRI), and other techniques. Image data representing an anatomical feature (e.g., an aorta) may be automatically segmented to obtain mask data for the anatomical feature. The mask data may undergo automated centerline regression to obtain centerline data for the anatomical feature. Automated curved planar reformatting, using the centerline data, may be applied to the original image data and/or the mask data. The curved planar reformation results may be subjected to automated segmentation. The resulting image data set may be used for such purposes as visualization, disease detection, measurement of feature, and/or tracking the anatomical feature over time.
Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
BACKGROUND: The aim of this study was to summarize the optimal strategy for early feeding in patients with acute pancreatitis.
METHODS: The search was undertaken in electronic databases, which compared early with delayed feeding in acute pancreatitis. The primary outcome was the length of hospital stay (LOHS). The second outcomes were intolerance of refeeding, mortality, and total cost of each patient. This meta-analysis followed the "Preferred Reporting Items for Systematic Reviews and Meta-analyses" guideline. Research is registered by PROSPERO, CRD42020192133.
RESULTS: A total of 20 trials involving 2168 patients were included, randomly assigned to the early feeding group (N = 1033) and delayed feeding group (N = 1135). The LOHS was significantly lower in the early feeding group than the delayed feeding group (mean difference: -2.35, 95% CI: -2.89 to -1.80; P < 0.0001), no matter the mild or severe subgroup ( Pint = 0.69). The secondary outcome of feeding intolerance and mortality were no significant difference (risk ratio: 0.96, 0.40 to 2.16, P = 0.87 and 0.91, 0.57 to 1.46, P = 0.69; respectively). Moreover, the hospitalization cost was significantly less in the early feeding group, resulting in an average savings of 50%. In patients with severe pancreatitis, early feeding after 24 hours may be beneficial ( Pint = 0.001).
CONCLUSION: Early oral feeding can significantly reduce the LOHS and hospitalization costs in patients with acute pancreatitis without increasing feeding intolerance or mortality. In patients with severe pancreatitis, early feeding after 24 hours may be beneficial.